Cargando…

Risk factors for progression to castration-resistant prostate cancer in metastatic prostate cancer patients

Purpose: To investigate the risk factors for progression to castration-resistant prostate cancer (CRPC) in metastatic prostate cancer (mPCa) patients who underwent androgen deprivation therapy (ADT). Methods: We analyzed 216 patients with mPCa who underwent ADT between January 2006 and December 2015...

Descripción completa

Detalles Bibliográficos
Autores principales:	Lin, Ting-Ting, Chen, Ye-Hui, Wu, Yu-Peng, Chen, Shao-Zhan, Li, Xiao-Dong, Lin, Yun-Zhi, Chen, Shao-Hao, Zheng, Qing-Shui, Wei, Yong, Xu, Ning, Xue, Xue-Yi
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Ivyspring International Publisher 2019
Materias:	Research Paper
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6775699/ https://www.ncbi.nlm.nih.gov/pubmed/31632505 http://dx.doi.org/10.7150/jca.30731

Ejemplares similares

Identification of marker genes and cell subtypes in castration-resistant prostate cancer cells
por: Lin, Xiao-Dan, et al.
Publicado: (2021)

Body composition parameters were associated with response to abiraterone acetate and prognosis in patients with metastatic castration‐resistant prostate cancer
por: Ke, Zhi‐Bin, et al.
Publicado: (2023)

Bipolar transurethral enucleation and resection of the prostate versus bipolar resection of the prostate for prostates larger than 60gr: A retrospective study at a single academic tertiary care center
por: Wei, Yong, et al.
Publicado: (2016)

Predictors for progression of metastatic prostate cancer to castration-resistant prostate cancer in Indians
por: Sureka, Sanjoy Kumar, et al.
Publicado: (2016)

Identification of Prostate Cancer-Related Circular RNA Through Bioinformatics Analysis
por: Wu, Yu-Peng, et al.
Publicado: (2020)

Development and validation of hub genes for lymph node metastasis in patients with prostate cancer
por: Xu, Ning, et al.
Publicado: (2020)

Risk factors of developing visceral metastases at diagnosis in prostate cancer patients
por: Xu, Ning, et al.
Publicado: (2019)

Older Age and Larger Prostate Volume Are Associated with Stress Urinary Incontinence after Plasmakinetic Enucleation of the Prostate
por: Xu, Ning, et al.
Publicado: (2017)

Treatment-Emergent Co-Morbidities and Survival in Patients With Metastatic Castration-Resistant Prostate Cancer Receiving Abiraterone or Enzalutamide
por: Lin, Yi-Ting, et al.
Publicado: (2021)

The cost impact of disease progression to metastatic castration-sensitive prostate cancer
por: Trinh, Quoc-Dien, et al.
Publicado: (2022)

ARPC1A correlates with poor prognosis in prostate cancer and is up-regulated by glutamine metabolism to promote tumor cell migration, invasion and cytoskeletal changes
por: Chen, Ye-Hui, et al.
Publicado: (2023)

Development and Validation of Novel Biomarkers Related to M2 Macrophages Infiltration by Weighted Gene Co-Expression Network Analysis in Prostate Cancer
por: Xu, Ning, et al.
Publicado: (2021)

Up‐regulation of LIMK1 expression in prostate cancer is correlated with poor pathological features, lymph node metastases and biochemical recurrence
por: Huang, Jin‐Bei, et al.
Publicado: (2020)

Upregulation of erythropoietin and erythropoietin receptor in castration-resistant progression of prostate cancer
por: Ye, Chen, et al.
Publicado: (2019)

Kinesin family member 18B regulates the proliferation and invasion of human prostate cancer cells
por: Wu, Yu-Peng, et al.
Publicado: (2021)

High Tumor Burden Predicts Poor Response to Enzalutamide in Metastatic Castration-Resistant Prostate Cancer Patients
por: Hsieh, Yu-Ting, et al.
Publicado: (2021)

Impact of Time to Castration Resistance on Cytoreductive Radiotherapy in Metastatic Castration-Resistant Prostate Cancer
por: Mai, Lixin, et al.
Publicado: (2020)

Downregulation of LOX promotes castration-resistant prostate cancer progression via IGFBP3
por: Chen, Xuanrong, et al.
Publicado: (2021)

Radium-223 in metastatic castration resistant prostate cancer
por: Vuong, Winston, et al.
Publicado: (2014)

Treatment sequencing in metastatic castrate-resistant prostate cancer
por: Sartor, Oliver, et al.
Publicado: (2014)

Abiraterone in the treatment of metastatic castration-resistant prostate cancer
por: Mostaghel, Elahe A
Publicado: (2014)

Enzalutamide for patients with metastatic castration-resistant prostate cancer
por: Ramadan, Wijdan H, et al.
Publicado: (2015)

Enzalutamide for the treatment of metastatic castration-resistant prostate cancer
por: Rodriguez-Vida, Alejo, et al.
Publicado: (2015)

PSMA theragnostics for metastatic castration resistant prostate cancer
por: Song, Hong, et al.
Publicado: (2022)

Risk Factors for Pathologically Confirmed Lymph Nodes Metastasis in Patients With Clinical T2N0M0 Stage Prostate Cancer
por: Xu, Ning, et al.
Publicado: (2020)

Utilization and Outcomes of Surgical Castration in Comparison to Medical Castration in Metastatic Prostate Cancer
por: Garje, Rohan, et al.
Publicado: (2019)

Comparative Effectiveness of Abiraterone and Enzalutamide in Patients With Metastatic Castration-Resistant Prostate Cancer in Taiwan
por: Li, Pei-Yu, et al.
Publicado: (2022)

Predictors Of Postoperative Lower Urinary Tract Symptoms Improvements In Patient With Small-Volume Prostate And Bladder Outlet Obstruction
por: Li, Xiao-Dong, et al.
Publicado: (2019)

Prognostic values of clinicopathological characteristics and survival outcomes in prostate infiltrating ductal carcinoma: a population-based study
por: Wu, Yu-Peng, et al.
Publicado: (2017)

Inhibition of LDHA suppresses tumor progression in prostate cancer
por: Xian, Zhi-Yong, et al.
Publicado: (2015)

Prostate radiation in non-metastatic castrate refractory prostate cancer provides an interesting insight into biology of prostate cancer
por: Pascoe, Abigail C, et al.
Publicado: (2012)

HTA and Reimbursement Status of Metastatic Hormone‑Sensitive Prostate Cancer, Non-Metastatic Castration-Resistant Prostate Cancer, and Metastatic Castration-Resistant Prostate Cancer Treatments in Europe: A Patient Access Landscape Review
por: Bencina, Goran, et al.
Publicado: (2023)

Pattern of Clinical Progression Until Metastatic Castration-Resistant Prostate Cancer: An Epidemiological Study from the European Prostate Cancer Registry
por: Verry, Camille, et al.
Publicado: (2022)

Prognostic Impacts of Metastatic Site and Pain on Progression to Castrate Resistance and Mortality in Patients with Metastatic Prostate Cancer
por: Koo, Kyo Chul, et al.
Publicado: (2015)

Increased Paxillin expression in prostate cancer is associated with advanced pathological features, lymph node metastases and biochemical recurrence
por: Zheng, Qing-Shui, et al.
Publicado: (2018)

Regression of Castration-Resistant Prostate Cancer by a Novel Compound HG122
por: Cong, Xiaonan, et al.
Publicado: (2021)

Reduced Connexin 43 expression is associated with tumor malignant behaviors and biochemical recurrence-free survival of prostate cancer
por: Xu, Ning, et al.
Publicado: (2016)

Prostate-Specific Membrane Antigen Uptake and Survival in Metastatic Castration-Resistant Prostate Cancer
por: Vlachostergios, Panagiotis J., et al.
Publicado: (2021)

Identification of key DNA methylation-driven genes in prostate adenocarcinoma: an integrative analysis of TCGA methylation data
por: Xu, Ning, et al.
Publicado: (2019)

Update on options for treatment of metastatic castration-resistant prostate cancer
por: Vishnu, Prakash, et al.
Publicado: (2010)

Cannot write session to /tmp/vufind_sessions/sess_uubuns6ruqfvrp0ocoq5kv6kpq